Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The MSD DPhil Day is an annual symposium showcasing the best student work from across the largest division of the University of Oxford. This year was no exception, and on Friday 20th July students from a wide range of scientific backgrounds came together to display their work to a uniquely broad audience.

Thirteen short talks and forty posters were presented and judged by generous volunteer post-docs. Because the overall quality of submissions was very high, it was difficult to pick winners. However, those awarded prizes generally combined rigorous and creative science with excellent communication skills.

In between short talks, a lively panel discussion was chaired by Afsie Sabokbar which focussed largely on the future of scientific publishing, with contributions from past and present editors of Science, The Lancet, and BMJ. We thank our panellists for their impassioned contributions and empathy for students.

The day closed with a keynote speech from Professor Kevin Marsh, senior advisor to the African Academy of Sciences and winner of numerous prizes for his contributions to health in Africa. Professor Marsh used his speech to challenge common misconceptions about the continent. He outlined the rapid socioeconomic change ongoing, and discussed the development of local scientific infrastructure.

The Committee would like to thank all students who attended and especially those who shared their work. Special thanks is also due to Louise Samson, Amanda King, Afsie Sabokbar. 

2018 DPhil day2.jpgBest talks: 1st prize Lisa Simpson (Division of Cardiovascular Medicine, RDM, pictured)

2nd prize Laura Grima (Nuffield Department of Clinical Neurosciences and Experimental Psychology)

Best posters: 1st prize Valentina Gifford (The Kennedy Institute, NDORMS)

2nd prize Rose Hodgson (Centre for Cellular and Molecular Physiology, NDM)

Committee: Caitlin O’Brian Ball, Robert Donat, Deniz Gursul, Ryan Hoyle, Di Hu, Delphine Nzelle Kayem, Peter Liu, Jeff Liu, Jolynne Mokaya, Becky Im, Xanita Saayman, Paolo Spingardi, Sandeep Unwith

 

Similar stories

Drug could help diabetic hearts recover after heart attack - Oxford research

Researchers at the University of Oxford have identified a drug that could ultimately help improve heart function in people with diabetes who have heart attacks.

Largest ever global study of tuberculosis identifies genetic causes of drug resistance

Using cutting-edge genomic sequencing techniques, researchers at the University of Oxford have identified almost all the genomic variation that gives people resistance to 13 of the most common tuberculosis (TB) drug treatments.

Peter Horby receives prestigious award for outstanding service to public health

The Faculty of Public Health (FPH) has awarded its prestigious Alwyn Smith Prize to Professor Sir Peter Horby (Nuffield Department of Medicine) for 2020/2021 in recognition of his outstanding service to public health as a global leader in epidemic science.

Six new Fellowships announced as part of Oxford-Bristol Myers Squibb Fellowships Programme

The Oxford - Bristol Myers Squibb (BMS) Fellowships Programme continued to demonstrate significant progress over the last year, despite the challenges associated with the global pandemic, including restricted lab access and work from home guidance. Today, we are pleased to announce six new Oxford-BMS Fellowships for 2021.

Researchers set out steps to address mental health effects of the pandemic on young people

Researchers have outlined 14 steps that schools, mental health services and policymakers can take to help children and young people whose mental health has been affected by the COVID-19 pandemic.

Anti-cancer drug derived from fungus shows promise in clinical trials

A new industry-academic partnership between the University of Oxford and biopharmaceutical company NuCana as found that chemotherapy drug NUC-7738, derived from a Himalayan fungus, has 40 times greater potency for killing cancer cells than its parent compound.